Allergan rose $3.66 or 2.9 percent, to $131.46. Baxter International Inc. rose$. 09 or. 1 percent, to $73.45. Boston Scientific Corp. rose$. 15 or 1.1 percent, to $13.50.» Read More
Oct 28- Edwards Lifesciences Corp on Monday reported higher-than-expected quarterly earnings, but investors were disappointed with the pace of U.S. sales of its newest artificial heart valves, sending its shares down more than 4 percent.
Oct 28- Edwards Lifesciences Corp on Monday reported higher-than-expected quarterly earnings as it benefited from strong sales of artificial heart valves that are implanted without major invasive surgery. Third-quarter net income rose to $77 million, or 68 cents per share, from $69 million, or 58 cents per share, a year earlier.
Oct 25- The U.S. Food and Drug Administration has approved Abbott Laboratories' MitraClip medical device, used to stop heart valve leakage in patients deemed unable to endure valve repair through open heart surgery, the company said on Friday. "We think longer term in the U.S., could be a $500 million product," said RBC Capital Markets analyst Glenn Novarro.
Oct 25- Abbott Laboratories said on Friday that the U.S. Food and Drug Administration approved its MitraClip medical device, used to stop heart valve leakage. A slim majority of advisers to the FDA had recommended approval of the implantable heart device, as some had questioned whether it would be effective for its intended use.
WASHINGTON, Oct 24- Medical device maker Stryker Corp will pay $13.2 million to settle civil charges the company bribed doctors and government officials to win business in five different countries, U.S. regulators said Thursday.
WASHINGTON, Oct 24- Medical device maker Stryker Corp will pay $13.2 million to settle civil charges alleging the company bribed doctors and government officials to win business in five different countries, U.S. regulators said Thursday.
Oct 23- Medical device maker Varian Medical Systems Inc reported lower-than-expected fourth-quarter results as demand for its products fell due to uncertainties related to U.S. healthcare reforms and reimbursement cuts. The company's fourth-quarter net earnings fell 2.4 percent to $117.3 million or $1.08 per share.
Proposals to toughen up European Union legislation on medical devices followed a 2011 scandal involving France's now defunct Poly Implant Prothese, which for up to a decade made substandard breast implants that were used by hundreds of thousands of women worldwide.
A detailed look at how a tax on medical devices divided so many over the White House's Affordable Care Act.
JPMorgan Chase, the Bill & Melinda Gates Foundation and others have launched an investment fund focused on late-stage healthcare technology trials.
A research project that gathers more information from hospital monitors than ever before is improving the prognosis of premature infants.
A new Web company is offering to connect inventors of smaller medical devices with people who can give them the cash they need to get off the ground.
Community Health Systems announced it would buy Health Management Associates in a deal valued at approximately $7.6 billion, including about $3.7 billion in debt.
Intuitive Surgical is down about 18 percent today after pre-announcing a huge miss Monday, CNBC's Herb Greenberg brings everyone up to speed; and Jason Mills, analyst at Canaccord Genuity, explains why he downgraded the stock.
Jim Cramer believes this company is about to create immense value with the stroke of a pen.
When architect Michael Graves realized he would spend the rest of his life in a wheelchair, he set out to improve medical design. This week Stryker unveils his wheelchair.
Bristol-Myers Squibb and Merck stocks climbed higher Monday as analysts said billions stood to be made from treatment breakthroughs.
Americans accustomed to immediate access to the newest technology may be shocked to find that is not the case when it comes to devices that treat ailing hearts.
Cramer’s convinced the best way to for this health care company to maximize shareholder value is to break up.
The rise of "superbugs," and pressure from the government and insurers, is driving hospitals to try all sorts of new approaches to stop their spread.